Skip to main content

Specialty Pharmacy

  • WHO approves Mylan generic HIV drugs for use in developing world

    PITTSBURGH — The World Health Organization has approved three generic second-line treatments for HIV made by Mylan, the drug maker said Tuesday. The drugs will be delivered to people in developing countries living with HIV and AIDS.

  • Second phase-3 study of TC-5214 did not meet primary endpoint

    WINSTON-SALEM, N.C. — AstraZeneca and Targacept released results of the second of four phase-3 clinical trials that investigated the efficacy and tolerability of a drug that could serve as an adjunct therapy to major depressive disorder patients that had an inadequate response to initial antidepressant therapies.

  • Prescription drug access remained stable between 2007 and 2010, study finds

    WASHINGTON — One-in-eight Americans didn't fill prescriptions last year because they couldn't afford to, but despite difficulties with the economy, that proportion remained level, according to a new study conducted by the Center for Studying Health System Change and funded by the Robert Wood Johnson Foundation.

  • US Bioservices receives Specialty Pharmacy Accreditation

    VALLEY FORGE, Pa. — US Bioservices, the specialty pharmacy of AmerisourceBergen, on Monday announced that it had received the Specialty Pharmacy Accreditation from URAC, a Washington-based healthcare accrediting organization that establishes quality standards for the healthcare industry.

  • 'Pharmacist Sentiment Report' gets inside the heads of today’s busiest pharmacists

    NEW YORK — What new prescription and OTC drugs are top of mind among retail pharmacists? How often do pharmacists REALLY recommend private label?

  • STDs becoming more prevalent across baby boomer demographic

    PITMAN, N.J. — According to an article in the November/December issue of the journal Medical-Surgical Nursing, rates of HIV/AIDS, herpes, syphilis, human papilloma virus and other STDs are climbing steadily across men and women older than 50 years. 

  • FDA to review patch for HIV-related pain

    SAM MATEO, Calif. — A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.

    NeurogesX said Thursday that the FDA Anesthetic and Analgesic Drug Products Advisory Committee would meet on Feb. 9, 2012, to review the patch drug Qutenza (capsaicin) as a treatment for pain associated with HIV-associated peripheral neuropathy, or HIV-PN.

    The drug currently is approved for treating pain associated with postherpetic neuralgia.

  • Diplomat Specialty Pharmacy hires Craig Stephens

    FLINT, Mich. — Diplomat Specialty Pharmacy has hired Craig Stephens as group VP business development and trade relations, the company said Wednesday.

X
This ad will auto-close in 10 seconds